Zacks Investment Research downgraded Global Medical REIT Inc (NASDAQ:GMRE) to Sell in a report released today.
- Updated: March 20, 2017
Zacks Investment Research has downgraded Global Medical REIT Inc (NASDAQ:GMRE) to Sell in a report released on Monday March 20, 2017.
Having a price of $8.32, Global Medical REIT Inc (NASDAQ:GMRE) traded -0.24% lower on the day. With the last stock price down -6.63% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.04% over the same period. GMRE has recorded a 50-day average of $8.48 and a two hundred day average of $8.91. Trade Volume was down over the average, with 48,958 shares of GMRE changing hands under the typical 111,251
Recent Performance Chart
Global Medical REIT Inc has with a one year low of $6.73 and a one year high of $11.38 and has a market capitalization of $0.
General Company Details For Global Medical REIT Inc (NASDAQ:GMRE)
Global Medical REIT Inc. focuses on operating as a real estate investment trust. The Company is engaged primarily in the acquisition and leasing of licensed purpose-built healthcare facilities in certain markets with various clinical operators. The Company seeks to invest in these purpose-built, specialized facilities, such as surgery centers, specialty hospitals and outpatient treatment centers. Its tenant-operators are physician group tenant-operators, community hospital tenant-operators and corporate medical treatment chain operators. Its properties include a six building, 52,266 square foot medical clinic portfolio in Tennessee; a combined approximately 27,190 square foot surgery center and medical office building located in West Mifflin, Pennsylvania; an approximately 8,840 square foot medical office building known as the Orthopedic Surgery Center, located in Asheville, North Carolina, and a 56-bed long term acute care hospital located at 1870 South 75th Street, Omaha, Nebraska.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.